{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T03:29:55Z","timestamp":1790566195029,"version":"4.1.0"},"reference-count":141,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Gastric cancer (GC) poses a major global health challenge, marked by high incidence and mortality rates. Conventional treatments such as surgery, chemotherapy, and targeted therapies show limited effectiveness in patients at advanced stages. As a result, immunotherapy has emerged as a promising strategy in the battle against cancer. In recent years, immunotherapy has flourished, with immune checkpoint inhibitors becoming widely applied in GC, while other immunotherapies are also rapidly advancing in clinical development, providing new therapeutic options for patients. The introduction of immunotherapy has profoundly changed the approach to GC treatment, with the expectation that additional immunotherapies will be developed in the near future. However, the clinical effectiveness of these therapies remains constrained due to the complexity of the tumor microenvironment (TME) in GC, the significant heterogeneity among patients, as well as the occurrence of immune therapy resistance and adverse reactions. This review provides an overview of recent advancements in GC immunotherapy, focusing on ICIs, adoptive cell therapy, and tumor vaccines. Key challenges such as patient selection, biomarker development, and combination therapy optimization are also discussed. In the future, a deeper exploration of the TME characteristics of GC and the implementation of personalized and precise immunotherapy are expected to further improve therapeutic outcomes and patient prognosis.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1592733","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T01:23:34Z","timestamp":1747790614000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Advancements and challenges in immunotherapy for gastric cancer: current approaches and future directions"],"prefix":"10.3389","volume":"16","author":[{"given":"Wenyu","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingzheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zehao","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqian","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Zha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deqiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"6664","DOI":"10.3390\/ijms23126664","article-title":"Immunotherapy as a therapeutic strategy for gastrointestinal cancer\u2014Current treatment options and future perspectives","volume":"23","author":"Koustas","year":"2022","journal-title":"IJMS"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jncc.2024.05.001","article-title":"Comparative study of cancer profiles between 2020 and 2022 using global cancer statistics (GLOBOCAN)","volume":"4","author":"Cao","year":"2024","journal-title":"J Natl Cancer Cent"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1097\/CEJ.0000000000000262","article-title":"Jiangsu Four Cancers Study: a large case-control study of lung, liver, stomach, and esophageal cancers in Jiangsu Province, China","volume":"26","author":"Zhao","year":"2017","journal-title":"Eur J Cancer Prev"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-13-1057","article-title":"Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention","volume":"23","author":"Karimi","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B5","doi-asserted-by":"publisher","first-page":"591","DOI":"10.22034\/APJCP.2018.19.3.591","article-title":"Risk factors for gastric cancer: A systematic review","volume":"19","author":"Yusefi","year":"2018","journal-title":"Asian Pac J Cancer Prev"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000001474","article-title":"Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020","volume":"134","author":"Cao","year":"2021","journal-title":"Chin Med J (Engl)"},{"key":"B7","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13045-023-01451-3","article-title":"Gastric cancer treatment: recent progress and future perspectives","volume":"16","author":"Guan","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-1408","article-title":"Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA): A phase II study evaluating an individualized treatment strategy for metastatic disease","volume":"11","author":"Catenacci","year":"2021","journal-title":"Cancer Discov"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31288-5","article-title":"Gastric cancer","volume":"396","author":"Smyth","year":"2020","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v30.i21.2734","article-title":"Application of immune checkpoint inhibitors and microsatellite instability in gastric cancer","volume":"30","author":"Yan","year":"2024","journal-title":"World J Gastroenterol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1172\/JCI83871","article-title":"Cancer immunotherapy: harnessing the immune system to battle cancer","volume":"125","author":"Yang","year":"2015","journal-title":"J Clin Investig"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/nature10673","article-title":"Cancer immunotherapy comes of age","volume":"480","author":"Mellman","year":"2011","journal-title":"Nature"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA A Cancer J Clinic"},{"key":"B14","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3892\/or.2024.8847","article-title":"Role and value of the tumor microenvironment in the progression and treatment resistance of gastric cancer (Review)","volume":"53","author":"Yun","year":"2025","journal-title":"Oncol Rep"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1097\/PAI.0000000000000423","article-title":"HER2 status in gastric and gastroesophageal junction cancer: results of the large, multinational HER-EAGLE study","volume":"26","author":"Kim","year":"2018","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2024.2407963","article-title":"The missing link between cancer stem cells and immunotherapy","volume":"40","author":"Ali","year":"2024","journal-title":"Curr Med Res Opin"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2024.03.008","article-title":"Gastric cancer immunosuppressive microenvironment heterogeneity: implications for therapy development","volume":"10","author":"Yasuda","year":"2024","journal-title":"Trends Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1016817","article-title":"Tumor microenvironment-mediated immune tolerance in development and treatment of gastric cancer","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.73","article-title":"The biology and function of fibroblasts in cancer","volume":"16","author":"Kalluri","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"B20","doi-asserted-by":"publisher","first-page":"11735","DOI":"10.3390\/ijms252111735","article-title":"Molecular mechanism for Malignant progression of gastric cancer within the tumor microenvironment","volume":"25","author":"Matsuoka","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B21","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41525-021-00249-x","article-title":"Immune cell infiltration signatures identified molecular subtypes and underlying mechanisms in gastric cancer","volume":"6","author":"Lin","year":"2021","journal-title":"NPJ Genom Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"6560","DOI":"10.3390\/ijms22126560","article-title":"The impact of the tumor microenvironment on macrophage polarization in cancer metastatic progression","volume":"22","author":"Wang","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B23","doi-asserted-by":"publisher","first-page":"537","DOI":"10.3892\/ol.2024.14670","article-title":"T lymphocyte\u2212related immune response and immunotherapy in gastric cancer (Review)","volume":"28","author":"Zhang","year":"2024","journal-title":"Oncol Lett"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2020.5042","article-title":"Immunological potential of tertiary lymphoid structures surrounding the primary tumor in gastric cancer","volume":"57","author":"Yamakoshi","year":"2020","journal-title":"Int J Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"108735","DOI":"10.1016\/j.intimp.2022.108735","article-title":"Peritumoral TIGIT+CD20+ B cell infiltration indicates poor prognosis but favorable adjuvant chemotherapeutic response in gastric cancer","volume":"108","author":"Liu","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1969767","DOI":"10.1080\/2162402X.2021.1969767","article-title":"Single-cell profiling of infiltrating B cells and tertiary lymphoid structures in the TME of gastric adenocarcinomas","volume":"10","author":"Jia","year":"2021","journal-title":"Oncoimmunology"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1069936","article-title":"Gastric cancer cells inhibit natural killer cell proliferation and induce apoptosis via prostaglandin E2","volume":"5","author":"Li","year":"2016","journal-title":"Oncoimmunology"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.927464","article-title":"Percentage of natural killer (NK) cells in peripheral blood is associated with prognosis in patients with gastric cancer: A retrospective study from a single center","volume":"27","author":"Xie","year":"2021","journal-title":"Med Sci Monit"},{"key":"B29","doi-asserted-by":"publisher","first-page":"104469","DOI":"10.1016\/j.cellimm.2021.104469","article-title":"Overexpression of DAPK1-mediated inhibition of IKK\u03b2\/CSN5\/PD-L1 axis enhances natural killer cell killing ability and inhibits tumor immune evasion in gastric cancer","volume":"372","author":"Guo","year":"2022","journal-title":"Cell Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noac138","article-title":"Dysfunctional dendritic cells limit antigen-specific T cell response in glioma","volume":"25","author":"Friedrich","year":"2023","journal-title":"Neuro Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13073-023-01259-3","article-title":"GITR and TIGIT immunotherapy provokes divergent multicellular responses in the tumor microenvironment of gastrointestinal cancers","volume":"15","author":"Sathe","year":"2023","journal-title":"Genome Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.04.011","article-title":"Characterizing diversity in the tumor-immune microenvironment of distinct subclasses of gastroesophageal adenocarcinomas","volume":"31","author":"Derks","year":"2020","journal-title":"Ann Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"560","DOI":"10.3390\/cancers16030560","article-title":"Therapeutic immunomodulation in gastric cancer","volume":"16","author":"Akkanapally","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.47162\/RJME.64.3.03","article-title":"Tumor angiogenesis in gastric cancer","volume":"64","author":"Giubelan","year":"2023","journal-title":"Rom J Morphol Embryol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.matbio.2024.06.004","article-title":"Cancer-associated fibroblasts promote proliferation, angiogenesis, metastasis and immunosuppression in gastric cancer","volume":"132","author":"Li","year":"2024","journal-title":"Matrix Biol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/cas.v111.8","article-title":"Tumor microenvironment in gastric cancers","volume":"111","author":"Oya","year":"2020","journal-title":"Cancer Sci"},{"key":"B37","doi-asserted-by":"publisher","first-page":"3686","DOI":"10.3390\/ijms21103686","article-title":"Role of extracellular matrix in gastrointestinal cancer-associated angiogenesis","volume":"21","author":"Andreuzzi","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/nrm3902","article-title":"Extracellular matrix assembly: a multiscale deconstruction","volume":"15","author":"Mouw","year":"2014","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3390\/cells9020394","article-title":"The extracellular matrix: an accomplice in gastric cancer development and progression","volume":"9","author":"Moreira","year":"2020","journal-title":"Cells"},{"key":"B40","doi-asserted-by":"publisher","first-page":"117229","DOI":"10.1016\/j.biopha.2024.117229","article-title":"Harnessing cytokines to optimize chimeric antigen receptor-T cell therapy for gastric cancer: Current advances and innovative strategies","volume":"178","author":"Cheng","year":"2024","journal-title":"BioMed Pharmacother"},{"key":"B41","doi-asserted-by":"publisher","first-page":"155665","DOI":"10.1016\/j.prp.2024.155665","article-title":"TNF-\u03b1, and TNFRs in gastrointestinal cancers","volume":"263","author":"Mozooni","year":"2024","journal-title":"Pathol Res Pract"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1111\/eci.v54.11","article-title":"The implicated role of GDF15 in gastrointestinal cancer","volume":"54","author":"Xue","year":"2024","journal-title":"Eur J Clin Invest"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1431495","article-title":"The role of IL-37 in gastrointestinal diseases","volume":"15","author":"Wang","year":"2024","journal-title":"Front Immunol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"156675","DOI":"10.1016\/j.cyto.2024.156675","article-title":"The CXCR2 chemokine receptor: A new target for gastric cancer therapy","volume":"181","author":"Kang","year":"2024","journal-title":"Cytokine"},{"key":"B45","doi-asserted-by":"publisher","first-page":"114616","DOI":"10.1016\/j.celrep.2024.114616","article-title":"Mutant TP53 switches therapeutic vulnerability during gastric cancer progression within interleukin-6 family cytokines","volume":"43","author":"Huber","year":"2024","journal-title":"Cell Rep"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112088","article-title":"Preoperative chemoradiotherapy for esophageal or junctional cancer","volume":"366","author":"van Hagen","year":"2012","journal-title":"N Engl J Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32557-1","article-title":"Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial","volume":"393","author":"Al-Batran","year":"2019","journal-title":"Lancet"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032125","article-title":"Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer","volume":"384","author":"Kelly","year":"2021","journal-title":"N Engl J Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00541-7","article-title":"Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study","volume":"25","author":"Shitara","year":"2024","journal-title":"Lancet Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2022-0093","article-title":"MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric\/gastroesophageal junction cancer","volume":"18","author":"Janjigian","year":"2022","journal-title":"Future Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.v234.11","article-title":"Synergistic antitumor effect of anti-PD-L1 combined with oxaliplatin on a mouse tumor model","volume":"234","author":"Golchin","year":"2019","journal-title":"J Cell Physiol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.4_suppl.446","article-title":"Primary results of the ICONIC phase 2 trial of perioperative FLOT plus avelumab (FLOT-A) in operable oesophagogastric adenocarcinoma (OGA)","author":"Gordon","year":"2023","journal-title":"J Clin Oncol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1186\/s12885-022-09623-z","article-title":"Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a phase II study (GASPAR)","volume":"22","author":"Dos Santos","year":"2022","journal-title":"BMC Cancer"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1111\/cts.70091","article-title":"Phase II study of perioperative camrelizumab and XELOX for locally advanced gastric or gastroesophageal junction adenocarcinoma","volume":"116","author":"He","year":"2024","journal-title":"Cancer Sci"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02721-w","article-title":"Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trial","volume":"30","author":"Yuan","year":"2024","journal-title":"Nat Med"},{"key":"B56","doi-asserted-by":"publisher","first-page":"4036","DOI":"10.3390\/cancers16234036","article-title":"Perioperative treatment in gastric cancer: A fast-changing field","volume":"16","author":"Costa","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00686","article-title":"Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair\/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: the GERCOR NEONIPIGA phase II study","volume":"41","author":"Andr\u00e9","year":"2023","journal-title":"J Clin Oncol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.4_suppl.358","article-title":"INFINITY: A multicentre, single-arm, multi-cohort, phase II trial of tremelimumab and durvalumab as neoadjuvant treatment of patients with microsatellite instability-high (MSI) resectable gastric or gastroesophageal junction adenocarcinoma (GAC\/GEJAC)","author":"Pietrantonio","year":"2025","journal-title":"J Clin Oncol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02758-x","article-title":"Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial","volume":"30","author":"Verschoor","year":"2024","journal-title":"Nat Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.4_suppl.296","article-title":"Phase II study of SHR1210 and trastuzumab in combination with CAPOX for neoadjuvant treatment of HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma","volume":"40","author":"Li","year":"2022","journal-title":"JCO"},{"key":"B62","doi-asserted-by":"publisher","first-page":"e16100","DOI":"10.1200\/JCO.2024.42.16_suppl.e16100","article-title":"Efficacy and safety of disitamab vedotin (RC48) combined with camrelizumab and S-1 for neoadjuvant therapy of locally advanced gastric cancer with HER2 overexpression: Preliminary results of a prospective, single-arm, phase II study","volume":"42","author":"Chai","year":"2024","journal-title":"JCO"},{"key":"B63","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1186\/s12885-019-5675-4","article-title":"EORTC-1203-GITCG - the \u201cINNOVATION\u201d-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group","volume":"19","author":"Wagner","year":"2019","journal-title":"BMC Cancer"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1172\/JCI180278","article-title":"DNA-PK inhibition enhances neoantigen diversity and increases T cell responses to immunoresistant tumors","volume":"134","author":"Nielsen","year":"2024","journal-title":"J Clin Invest"},{"key":"B65","doi-asserted-by":"publisher","first-page":"159096","DOI":"10.1016\/j.cej.2024.159096","article-title":"Enhancing immunotherapy using a synergistic T-lymphocyte and neutrophil-targeting activation (TNTa) strategy for triple-negative breast cancer treatment","volume":"505","author":"Zhang","year":"2025","journal-title":"Chem Eng J"},{"key":"B66","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s12957-025-03752-y","article-title":"Applications and challenges of immunotherapy in the management of gastric adenocarcinoma: current status and future perspectives","volume":"23","author":"Chen","year":"2025","journal-title":"World J Surg Oncol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-20-0338","article-title":"Enhancing the generation of eomeshi CD8+ T cells augments the efficacy of OX40- and CTLA-4\u2013targeted immunotherapy","volume":"9","author":"Emerson","year":"2021","journal-title":"Cancer Immunol Res"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2024.09.026","article-title":"PD-L1: From cancer immunotherapy to therapeutic implications in multiple disorders","volume":"32","author":"Lee","year":"2024","journal-title":"Mol Ther"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-032414-112049","article-title":"Coinhibitory pathways in immunotherapy for cancer","volume":"34","author":"Baumeister","year":"2016","journal-title":"Annu Rev Immunol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"17588359231186027","DOI":"10.1177\/17588359231186027","article-title":"The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition","volume":"15","author":"Kreidieh","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-cancerbio-061521-093717","article-title":"Advances in therapies targeting inhibitory checkpoint receptors: TIGIT, LAG-3, and beyond","volume":"8","author":"Healy","year":"2024","journal-title":"Annu Rev Cancer Biol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s12943-024-02179-5","article-title":"Current trends in sensitizing immune checkpoint inhibitors for cancer treatment","volume":"23","author":"Wei","year":"2024","journal-title":"Mol Cancer"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.3370","article-title":"Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial","volume":"6","author":"Shitara","year":"2020","journal-title":"JAMA Oncol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00892","article-title":"Phase III trial of avelumab maintenance after first-line induction chemotherapy versus continuation of chemotherapy in patients with gastric cancers: results from JAVELIN gastric 100","volume":"39","author":"Moehler","year":"2021","journal-title":"J Clin Oncol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31257-1","article-title":"Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial","volume":"392","author":"Shitara","year":"2018","journal-title":"Lancet"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.0013","article-title":"Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial","volume":"4","author":"Fuchs","year":"2018","journal-title":"JAMA Oncol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-018-00909-5","article-title":"Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study","volume":"22","author":"Bang","year":"2019","journal-title":"Gastric Cancer"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy264","article-title":"randomised trial of avelumab versus physician\u2019s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300","volume":"29","author":"Bang","year":"2018","journal-title":"Ann Oncol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31827-5","article-title":"Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Kang","year":"2017","journal-title":"Lancet"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-019-01034-7","article-title":"A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data","volume":"23","author":"Chen","year":"2020","journal-title":"Gastric Cancer"},{"key":"B81","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.3390\/jcm12072636","article-title":"Updated immunotherapy for gastric cancer","volume":"12","author":"Narita","year":"2023","journal-title":"J Clin Med"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30169-8","article-title":"First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial","volume":"21","author":"Janjigian","year":"2020","journal-title":"Lancet Oncol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.4013","article-title":"Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (G\/GEJ) cancer: Initial findings of the global phase 3 KEYNOTE-811 study","volume":"39","author":"Janjigian","year":"2021","journal-title":"JCO"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2408121","article-title":"Pembrolizumab in HER2-positive gastric cancer","volume":"391","author":"Janjigian","year":"2024","journal-title":"N Engl J Med"},{"key":"B85","doi-asserted-by":"publisher","first-page":"6002","DOI":"10.1038\/s41467-022-33267-z","article-title":"A single arm phase Ib\/II trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancer","volume":"13","author":"Lee","year":"2022","journal-title":"Nat Commun"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30326-0","article-title":"Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial","volume":"21","author":"Catenacci","year":"2020","journal-title":"Lancet Oncol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.08.1488","article-title":"1379P Margetuximab (M) with retifanlimab (R) in HER2+, PD-L1 + 1st-line unresectable\/metastatic gastroesophageal adenocarcinoma (GEA): MAHOGANY cohort A","volume":"32","author":"Catenacci","year":"2021","journal-title":"Ann Oncol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.2228","article-title":"Efficacy of ipilimumab vs FOLFOX in combination with nivolumab and trastuzumab in patients with previously untreated ERBB2-positive esophagogastric adenocarcinoma: the AIO INTEGA randomized clinical trial","volume":"8","author":"Stein","year":"2022","journal-title":"JAMA Oncol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"102415","DOI":"10.1016\/j.eclinm.2023.102415","article-title":"Disitamab vedotin (RC48) plus toripalimab for HER2-expressing advanced gastric or gastroesophageal junction and other solid tumors: a multicentre, open label, dose escalation and expansion phase 1 trial","volume":"68","author":"Wang","year":"2024","journal-title":"EClinicalMedicine"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.05.360","article-title":"448P Disitamab vedotin (RC48) combined with programmed death-1 inhibitor for pre-treated HER2 expressed (IHC 2+\/3+) advanced gastric cancer: A multi-center real-world study","volume":"35","author":"Yan","year":"2024","journal-title":"Ann Oncol"},{"key":"B91","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.ejca.2020.02.002","article-title":"Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric\/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study","volume":"129","author":"Kawazoe","year":"2020","journal-title":"Eur J Cancer"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"1864908","DOI":"10.1080\/2162402X.2020.1864908","article-title":"Anti-PD-1 antibody HX008 combined with oxaliplatin plus capecitabine for advanced gastric or esophagogastric junction cancer: a multicenter, single-arm, open-label, phase Ib trial","volume":"10","author":"Xu","year":"2020","journal-title":"Oncoimmunology"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1411571","article-title":"Cost-effectiveness analysis of first-line sintilimab plus chemotherapy vs. chemotherapy alone for unresectable advanced or metastatic gastric or gastroesophageal junction cancer in China","volume":"15","author":"Xiang","year":"2024","journal-title":"Front Pharmacol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.19918","article-title":"Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the ORIENT-16 randomized clinical trial","volume":"330","author":"Xu","year":"2023","journal-title":"JAMA"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-078876","article-title":"Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial","volume":"385","author":"Qiu","year":"2024","journal-title":"BMJ"},{"key":"B97","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy540","article-title":"Safety and efficacy of nivolumab in combination with S-1\/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric\/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4)","volume":"30","author":"Boku","year":"2019","journal-title":"Ann Oncol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00692-6","article-title":"Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Kang","year":"2022","journal-title":"Lancet Oncol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.28463","article-title":"First-line sugemalimab plus chemotherapy for advanced gastric cancer: the GEMSTONE-303 randomized clinical trial","volume":"333","author":"Zhang","year":"2025","journal-title":"JAMA"},{"key":"B101","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1200\/JCO.2022.40.4_suppl.308","article-title":"A phase Ib\/II, multicenter, open-label study of AK104, a PD-1\/CTLA-4 bispecific antibody, combined with chemotherapy (chemo) as first-line therapy for advanced gastric (G) or gastroesophageal junction (GEJ) cancer","volume":"40","author":"Ji","year":"2022","journal-title":"J Clin Oncol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.4031","article-title":"A phase Ib\/II, multicenter, open-label study of AK104, a PD-1\/CTLA-4 bispecific antibody, combined with chemotherapy (chemo) as first-line therapy for advanced gastric (G) or gastroesophageal junction (GEJ) cancer: 2-Year update data","author":"Shen","year":"2023","journal-title":"J Clin Oncol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.6212","article-title":"CheckMate-032 study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer","volume":"36","author":"Janjigian","year":"2018","journal-title":"J Clin Oncol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2790","article-title":"Analyses of PD-L1 and inflammatory gene expression association with efficacy of nivolumab \u00b1 Ipilimumab in gastric cancer\/gastroesophageal junction cancer","volume":"27","author":"Lei","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2443","article-title":"Safety and efficacy of durvalumab and tremelimumab alone or in combination in patients with advanced gastric and gastroesophageal junction adenocarcinoma","volume":"26","author":"Kelly","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01636","article-title":"First-line nivolumab and relatlimab plus chemotherapy for gastric or gastroesophageal junction adenocarcinoma: the phase II RELATIVITY-060 study","volume":"42","author":"Hegewisch-Becker","year":"2024","journal-title":"J Clin Oncol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-023-01104-2","article-title":"Immunology and immunotherapy in gastric cancer","volume":"23","author":"Xu","year":"2023","journal-title":"Clin Exp Med"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1007\/s13238-017-0384-8","article-title":"Effective and persistent antitumor activity of HER2-directed CAR-T cells against gastric cancer cells in vitro and xenotransplanted tumors in vivo","volume":"9","author":"Song","year":"2018","journal-title":"Protein Cell"},{"key":"B109","doi-asserted-by":"publisher","first-page":"217362","DOI":"10.1016\/j.canlet.2024.217362","article-title":"Emerging targets in gastric and pancreatic cancer: Focus on claudin 18.2","volume":"611","author":"Tojjari","year":"2024","journal-title":"Cancer Lett"},{"key":"B110","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1186\/s12876-023-02924-y","article-title":"CLDN18.2 expression and its impact on prognosis and the immune microenvironment in gastric cancer","volume":"23","author":"Wang","year":"2023","journal-title":"BMC Gastroenterol"},{"key":"B111","article-title":"The killing effect of novel bi-specific Trop2\/PD-L1 CAR-T cell targeted gastric cancer","volume":"9","author":"Zhao","year":"2019","journal-title":"Am J Cancer Res"},{"key":"B112","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13045-019-0704-y","article-title":"Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer","volume":"12","author":"Lv","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B113","doi-asserted-by":"publisher","first-page":"2033528","DOI":"10.1080\/2162402X.2022.2033528","article-title":"Comparing CAR and TCR engineered T cell performance as a function of tumor cell exposure","volume":"11","author":"Wachsmann","year":"2022","journal-title":"Oncoimmunology"},{"key":"B114","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12968\/hmed.2024.0759","article-title":"Advances in immunotherapy and targeted therapy for gastric cancer: A comprehensive review","volume":"86","author":"Yuan","year":"2025","journal-title":"Br J Hosp Med (Lond)"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.03095","article-title":"Therapeutic potential of natural killer cells in gastric cancer","volume":"9","author":"Du","year":"2018","journal-title":"Front Immunol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-0768","article-title":"Phase I trial of expanded, activated autologous NK-cell infusions with trastuzumab in patients with HER2-positive cancers","volume":"26","author":"Lee","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.64630","article-title":"Development of mesothelin-specific CAR NK-92 cells for the treatment of gastric cancer","volume":"17","author":"Cao","year":"2021","journal-title":"Int J Biol Sci"},{"key":"B118","article-title":"Research advances in immunotherapy for gastric cancer","volume":"51","author":"Xiong","year":"2024","journal-title":"Chin J Clin Oncol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00071","article-title":"Scoring system for tumor-infiltrating lymphocytes and its prognostic value for gastric cancer","volume":"10","author":"Zhang","year":"2019","journal-title":"Front Immunol"},{"key":"B120","doi-asserted-by":"publisher","first-page":"18824","DOI":"10.14670\/HH-18-824","article-title":"Intratumoral T cells are associated with prognosis and chemotherapy benefit in gastric cancer","author":"Liu","year":"2024","journal-title":"Histol Histopathol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2021-0285","article-title":"Cellular immunotherapy in gastric cancer: adoptive cell therapy and dendritic cell-based vaccination","volume":"14","author":"Faghfuri","year":"2022","journal-title":"Immunotherapy"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1267369","article-title":"Autologous CIK cells combined with chemotherapy as the first-line treatment for locally advanced or metastatic gastric cancer is safe and feasible","volume":"14","author":"Ma","year":"2023","journal-title":"Front Immunol"},{"key":"B123","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.imlet.2018.01.011","article-title":"Therapeutic cancer vaccines: From initial findings to prospects","volume":"196","author":"Song","year":"2018","journal-title":"Immunol Letters"},{"key":"B124","doi-asserted-by":"publisher","first-page":"2183510","DOI":"10.1155\/2019\/2183510","article-title":"A comprehensive survey of genomic alterations in gastric cancer reveals recurrent neoantigens as potential therapeutic targets","volume":"2019","author":"Chen","year":"2019","journal-title":"BioMed Res Int"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v21.i26.8052","article-title":"Conjugation of toll-like receptor-7 agonist to gastric cancer antigen MG7-Ag exerts antitumor effects","volume":"21","author":"Wang","year":"2015","journal-title":"World J Gastroenterol"},{"key":"B126","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12967-018-1501-z","article-title":"Gastric cancer vaccines synthesized using a TLR7 agonist and their synergistic antitumor effects with 5-fluorouracil","volume":"16","author":"Wang","year":"2018","journal-title":"J Transl Med"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1557\/jmr.2020.227","article-title":"Nanostructured lipid carrier delivering chlorins e6 as in situ dendritic cell vaccine for immunotherapy of gastric cancer","volume":"35","author":"Mao","year":"2020","journal-title":"J Mater Res"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1016\/j.soc.2019.02.007","article-title":"Oncolytic immunotherapy","volume":"28","author":"Hennessy","year":"2019","journal-title":"Surg Oncol Clin N Am"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1007\/s40291-021-00517-7","article-title":"Immuno-oncolytic viruses: emerging options in the treatment of colorectal cancer","volume":"25","author":"Kana","year":"2021","journal-title":"Mol Diagn Ther"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2020.03.022","article-title":"Efficacy of a third-generation oncolytic herpes virus G47\u0394 in advanced stage models of human gastric cancer","volume":"17","author":"Sugawara","year":"2020","journal-title":"Mol Ther Oncol"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006280","article-title":"Development of the oncolytic virus, CF33, and its derivatives for peritoneal-directed treatment of gastric cancer peritoneal metastases","volume":"11","author":"Yang","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2023.100734","article-title":"Peritoneal-directed chimeric oncolytic virus CF17 prevents Malignant ascites and improves survival in gastric cancer peritoneal metastases","author":"Yang","year":"2023","journal-title":"Mol Ther oncol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2020.06.021","article-title":"Boosting replication and penetration of oncolytic adenovirus by paclitaxel eradicate peritoneal metastasis of gastric cancer","volume":"18","author":"Ishikawa","year":"2020","journal-title":"Mol Ther Oncol"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1069204","article-title":"Identification of TGF-\u03b2 signaling-related molecular patterns, construction of a prognostic model, and prediction of immunotherapy response in gastric cancer","volume":"13","author":"Zeng","year":"2022","journal-title":"Front Pharmacol"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-024-01624-4","article-title":"Evolving strategies in the management of microsatellite instability-high\/mismatch repair deficient esophagogastric adenocarcinoma","volume":"27","author":"Balmaceda","year":"2025","journal-title":"Curr Oncol Rep"},{"key":"B136","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s12885-025-13589-z","article-title":"Effects of perioperative treatment of resectable adenocarcinoma of esophagogastric junction by immunotherapy (Adebrelimab) combined with chemotherapy (XELOX): protocol for a single-center, open-labeled study (AEGIS trial, neoadjuvant immunochemotherapy)","volume":"25","author":"Li","year":"2025","journal-title":"BMC Cancer"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1519545","article-title":"Nab-paclitaxel combined with cadonilimab (AK104) as second-line treatment for advanced gastric cancer: protocol for a phase II prospective, multicenter, single-arm clinical trial","volume":"16","author":"Wei","year":"2025","journal-title":"Front Immunol"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.935056","article-title":"Identification and validation of a novel cellular senescence-related lncRNA prognostic signature for predicting immunotherapy response in stomach adenocarcinoma","volume":"13","author":"Zeng","year":"2022","journal-title":"Front Genet"},{"key":"B139","doi-asserted-by":"publisher","first-page":"1984059","DOI":"10.1080\/2162402X.2021.1984059","article-title":"An open-label, randomized, multi-center study comparing the sequence of high dose aldesleukin (Interleukin-2) and ipilimumab (Yervoy) in patients with metastatic melanoma","volume":"10","author":"Hasanov","year":"2021","journal-title":"Oncoimmunology"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.9b10103","article-title":"Boosting natural killer cell-based cancer immunotherapy with selenocystine\/transforming growth factor-beta inhibitor-encapsulated nanoemulsion","volume":"14","author":"Liu","year":"2020","journal-title":"ACS Nano"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202106768","article-title":"3D printing scaffold vaccine for antitumor immunity","volume":"33","author":"Zhang","year":"2021","journal-title":"Adv Mater"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1592733\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T01:23:36Z","timestamp":1747790616000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1592733\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,21]]},"references-count":141,"alternative-id":["10.3389\/fimmu.2025.1592733"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1592733","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,21]]},"article-number":"1592733"}}